CMA Guideline Recommendations

Smiling brother and sister sitting together on couch

Chromosomal microarray has the highest diagnostic yield of any single clinically available test for children with developmental delay/intellectual disability or autism spectrum disorders and The American College of Medical Genetics (ACMG), the American Academy of Pediatricians (AAP), and the American Academy of Neurology (AAN) recommend CMA testing as a first-line genetic test for the initial postnatal evaluation of individuals with nonsyndromic developmental delay/intellectual disability, autism spectrum disorders, and multiple congenital anomalies.

Research shows that early intervention treatment services can greatly improve a child’s development. Consider ClariSure® Postnatal CMA testing from Quest Diagnostics to help guide patient management and make informed treatment decisions.

ACMG Guidelines:

ACMG guidelines for microarray use in the postnatal setting

ACMG Practice Guideline for array based technology utilization for detecting chromosomal abnormalities

Other Guidelines and Endorsements:

AAP statement of endorsement

AAN and CNS guidelines

American Society of Human Genetics consensus statement

AAN Template Coverage Policy on CMA for Intellectual Disabilities

Add ClariSure to Your Practice
If you are already a valued client of Quest Diagnostics, contact your local representative or call (866) MY-QUEST to ask about how to order ClariSure or fill out our form to speak to a highly trained neurology account executive in your area.